FGF21 and Fructose Challenge in Humans

Fasting Clinical Trial

Official title:

Fibroblast Growth Factor 21 and Fructose Challenge in Humans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02884791
• Other study ID #: 2015P000381
• Status: Completed
• Phase: N/A
• Start date: February 2016
• Est. completion date: May 30, 2023

Study information

• Verified date: August 2023
• Source: Beth Israel Deaconess Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary aim of this study is to examine the effect of acute ingestion of fructose on serum FGF21 levels. Subjects in this study will be lean volunteers and individuals with metabolic syndrome.

Description:

Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to 10 different sweet beverages, separated by 2 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: May 30, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria for lean subjects:

• Men and women ages 18-60

• BMI 19-25 kg/m2; 19-23 for Asian subjects

• Stable weight (variation < 3 kg within 6 months of screening visit)

• Ability to give informed consent

• Ability to follow verbal and written instructions in English

• Use of medically approved form of contraception (monophasic oral contraception, intra uterine device, surgical sterilization or 2 combined barrier methods)

Specific exclusion criteria for lean subjects:

• Fasting blood glucose >100; 2 hr OGTT blood glucose >140

• Fasting triglycerides >150

Inclusion criteria for metabolic syndrome subjects:

3 or more of the following (based on joint scientific statement by Alberti et al, 2009:

• Fasting triglycerides >150 mg/dl (or on treatment for elevated triglycerides)

• HDL cholesterol <40 mg/dl in men or <50 mg/dl in women

• Blood pressure > 130/85 (or antihypertensive treatment in a subject with history of hypertension)

• Fasting BG >100

• Elevated waist circumference ** see below for race and ethnic specifications

Men Women

• Asian or Central, South or Native American > 90 cm > 80 cm

• Non-Asian, Non-Latino United States > 102 cm > 88 cm

General Exclusion criteria

• Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria

• Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure)

• Uncontrolled hypertension (BP > 160/100 mmHg on or off antihypertensive medication)

• Marijuana or intravenous drug use

• Recent weight loss (> 3 kg within 6 months of the screening visit)

• Gastroparesis

• Inflammatory or irritable bowel disease

• Malignancy treated with chemotherapy within the past 3 years

• Depression or psychosis requiring hospitalization

• Renal insufficiency (creatinine clearance < 40 ml/min)

• Transaminases > 2x above the normal range

• Known liver disease

• Pregnancy within 6 months of the screening visit

• Lactation

• Failure to use medically approved contraceptive methods

• History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)

• Change in dose of thyroid hormone or antithyroidal medication within 3 months of screening visit

• History of alcohol abuse within the past 5 years

• Fructose intolerance

Exclusionary medications:

• Oral steroids

• Metformin

• Weight loss medications including nonprescription supplements

Related Conditions & MeSH terms

• Fasting

Intervention

Dietary Supplement:
• oral carbohydrate challenge
Participants will fast for 8 hours and then drink a beverage containing fructose.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Fibroblast Growth Factor 21 levels in human serum		5 hours